| Date |
Report No. |
Title |
| Date Sept. 23, 2011 |
Report No. GAO-11-836 |
Title
United States Government Accountability Office GAO
September 2011 Report to Congressional Committees DRUG PRICING Manufacturer Discounts in the 340B Program Offer Benefits, but Federal Oversight Needs Improvement GAO-11-836 September 2011 DRUG PRICING
Manufacturer Discounts in the 340B Program Offer Benefits, but Federal Oversight Needs Improvement
Highlights of GAO-11-836, a report to congression... |
| Date March 18, 2011 |
Report No. GAO-11-474R |
Title
United States Government Accountability Office Washington, DC 20548 March 18, 2011 Congressional Addressees: Subject: List of Selected Federal Programs That Have Similar or Overlapping Objectives, Provide Similar Services, or Are Fragmented Across Government Missions This report supplements our March 1, 2011, report Opportunities to Reduce Potential Duplication in Government Programs, Save Tax Dol... |
| Date March 3, 2011 |
Report No. GAO-11-441T |
Title
United States Government Accountability Office GAO
For Release on Delivery Expected at 9:30 a.m. EST Thursday, March 3, 2011 Testimony Before the House Committee on Oversight and Government Reform Opportunities to Reduce Potential Duplication in Government Programs, Save Tax Dollars, and Enhance Revenue
Statement of Gene L. Dodaro Comptroller General of the United States GAO-11-441T Mr. Chairman, ... |
| Date March 1, 2011 |
Report No. GAO-11-318SP |
Title
United States Government Accountability Office GAO
March 2011 Report to Congressional Addressees Opportunities to Reduce Potential Duplication in Government Programs, Save Tax Dollars, and Enhance Revenue GAO-11-318SP Contents Letter Section I GAO Identified Areas of Potential Duplication, Overlap, and Fragmentation, Which, if Effectively Addressed, Could Provide Financial and Other Benefits 1 5 S... |
| Date Dec. 22, 2009 |
Report No. GAO-10-201 |
Title
United States Government Accountability Office GAO
December 2009 Report to Congressional Requesters BRAND-NAME PRESCRIPTION DRUG PRICING Lack of Therapeutically Equivalent Drugs and Limited Competition May Contribute to Extraordinary Price Increases GAO-10-201 December 2009 BRAND-NAME PRESCRIPTION DRUG PRICING Highlights
Highlights of GAO-10-201, a report to congressional requesters Accountability... |
| Date Sept. 30, 2008 |
Report No. GAO-08-1074R |
Title
United States Government Accountability Office Washington, DC 20548 September 30, 2008 The Honorable Henry A. Waxman Chairman Committee on Oversight and Government Reform House of Representatives Subject: Medicare Part D Prescription Drug Coverage: Federal Oversight of Reported Price Concessions Data Dear Mr. Chairman: To help Medicare beneficiaries manage the rising cost of prescription drugs, Co... |
| Date Sept. 5, 2008 |
Report No. GAO-08-824 |
Title
United States Government Accountability Office GAO
September 2008 Report to Congressional Committees MEDICARE PART D LOW-INCOME SUBSIDY Assets and Income Are Both Important in Subsidy Denials, and Access to State and Manufacturer Drug Programs Is Uneven GAO-08-824 September 2008 MEDICARE PART D LOW-INCOME SUBSIDY Highlights
Highlights of GAO-08-824, a report to congressional committees Accountabil... |
